256 related articles for article (PubMed ID: 8442256)
1. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival.
Howard RJ; Pfaff WW; Brunson ME; Ramos EL; Peterson JC; Croker BP; Scornik JC; Parris CJ; Fennell RS
Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256
[No Abstract] [Full Text] [Related]
2. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
3. Pediatric renal transplantation in a single center from Brazil.
Abbud-Filho M; Ramalho H; Barberato JB; Silva ML; Yamazaki W; Salgueiro MC; Zerati-Fo M; D'Avila CL; Bezas AG
Transplant Proc; 1995 Apr; 27(2):1834. PubMed ID: 7725526
[No Abstract] [Full Text] [Related]
4. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
5. Accelerated acute rejection in renal allograft.
Han DJ; Yoon HS; Lee HM
Transplant Proc; 1996 Jun; 28(3):1455. PubMed ID: 8658738
[No Abstract] [Full Text] [Related]
6. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
[No Abstract] [Full Text] [Related]
7. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
8. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
9. Five-year experience with a triple drug protocol in renal transplantation.
Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
[No Abstract] [Full Text] [Related]
10. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies.
Abramowicz D; Norman DJ; Goldman M; De Pauw L; Kinnaert P; Kahana L; Thistlethwaite JR; Shield CF; Monaco AP; Vanherweghem JL
Transplant Proc; 1995 Feb; 27(1):852-3. PubMed ID: 7879204
[No Abstract] [Full Text] [Related]
11. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
12. High-dose cyclosporine A induction therapy in liver transplant recipients with normal postoperative renal function: a prospective study.
Cherqui D; Duvoux C; Salvat A; Lauzet JY; Metreau JM; Julien M; Fagniez PL; Dhumeaux D
Transplant Proc; 1995 Feb; 27(1):1134-5. PubMed ID: 7878824
[No Abstract] [Full Text] [Related]
13. Posttransplant renal allograft dysfunction as a prognostic factor in triple therapy-treated patients.
Pallardó LM; García J; Sánchez J; Górriz JL; Orero E; Calabuig F
Transplant Proc; 1992 Feb; 24(1):113-4. PubMed ID: 1539199
[No Abstract] [Full Text] [Related]
14. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
[No Abstract] [Full Text] [Related]
15. Strategy for improving retransplantation in the CyA era.
Dickerman R; Langley J; Brinker K; Trevino G; Melton L; Vergne-Marini P; Wilson PK
Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
[No Abstract] [Full Text] [Related]
16. Optimization of cyclosporine monotherapy--long-term graft function.
Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
[No Abstract] [Full Text] [Related]
17. Combined high and low dosing of OKT3 for treatment of rejection episodes in renal transplants.
Schweizer RT; Bartus S; Hull D; Perdrizet G; Roper L
Transplant Proc; 1994 Dec; 26(6):3141. PubMed ID: 7998094
[No Abstract] [Full Text] [Related]
18. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
19. Strategy for improvement of graft survival in kidney recipients of nonrelated living donors.
Távora ER; Lasmar EP; Vilaca SS; Figueiró JV; Bamberg A; Rocha LM; Costa MM; Bicalbo O; Souza E; Machado R
Transplant Proc; 1995 Apr; 27(2):1819-20. PubMed ID: 7725518
[No Abstract] [Full Text] [Related]
20. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
[No Abstract] [Full Text] [Related]
[Next] [New Search]
